Literature DB >> 26439305

P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.

Gerald J Spangrude1, Daniel Lewandowski2, Fabrizio Martelli3, Manuela Marra3, Maria Zingariello4, Laura Sancillo5, Rosa Alba Rana5, Anna Rita Migliaccio6,7.   

Abstract

Splenomegaly is a major manifestation of primary myelofibrosis (PMF) contributing to clinical symptoms and hematologic abnormalities. The spleen from PMF patients contains increased numbers of hematopoietic stem cells (HSC) and megakaryocytes (MK). These MK express high levels of P-selectin (P-sel) that, by triggering neutrophil emperipolesis, may cause TGF-β release and disease progression. This hypothesis was tested by deleting the P-sel gene in the myelofibrosis mouse model carrying the hypomorphic Gata1(low) mutation that induces megakaryocyte abnormalities that recapitulate those observed in PMF. P-sel(null) Gata1(low) mice survived splenectomy and lived 3 months longer than P-sel(WT) Gata1(low) littermates and expressed limited fibrosis and osteosclerosis in the marrow or splenomegaly. Furthermore, deletion of P-sel disrupted megakaryocyte/neutrophil interactions in spleen, reduced TGF-β content, and corrected the HSC distribution that in Gata1(low) mice, as in PMF patients, is abnormally expanded in spleen. Conversely, pharmacological inhibition of TGF-β reduced P-sel expression in MK and corrected HSC distribution. Spleens, but not marrow, of Gata1(low) mice contained numerous cKIT(pos) activated fibrocytes, probably of dendritic cell origin, whose membrane protrusions interacted with MK establishing niches hosting immature cKIT(pos) hematopoietic cells. These activated fibrocytes were not detected in spleens from P-sel(null) Gata1(low) or TGF-β-inhibited Gata1(low) littermates and were observed in spleen, but not in marrow, from PMF patients. Therefore, in Gata1(low) mice, and possibly in PMF, abnormal P-sel expression in MK may mediate the pathological cell interactions that increase TGF-β content in MK and favor establishment of a microenvironment that supports myelofibrosis-related HSC in spleen.
© 2015 AlphaMed Press.

Entities:  

Keywords:  Activated fibrocytes; Extramedullary hematopoiesis; Megakaryocytes; Myelofibrosis-related stem cells; P-selectin; TGF-β

Mesh:

Substances:

Year:  2015        PMID: 26439305     DOI: 10.1002/stem.2229

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  18 in total

1.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

Review 2.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

3.  Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Authors:  Jun Mori; Zoltan Nagy; Giada Di Nunzio; Christopher W Smith; Mitchell J Geer; Rashid Al Ghaithi; Johanna P van Geffen; Silke Heising; Luke Boothman; Bibian M E Tullemans; Joao N Correia; Louise Tee; Marijke J E Kuijpers; Paul Harrison; Johan W M Heemskerk; Gavin E Jarvis; Alexander Tarakhovsky; Arthur Weiss; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

4.  New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

Review 5.  The contribution of mouse models to the understanding of constitutional thrombocytopenia.

Authors:  Catherine Léon; Arnaud Dupuis; Christian Gachet; François Lanza
Journal:  Haematologica       Date:  2016-08       Impact factor: 9.941

6.  Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Authors:  Ilaria Ceglia; Amylou C Dueck; Francesca Masiello; Fabrizio Martelli; Wu He; Giulia Federici; Emanuel F Petricoin; Ann Zeuner; Camelia Iancu-Rubin; Rona Weinberg; Ronald Hoffman; John Mascarenhas; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2016-08-31       Impact factor: 3.084

Review 7.  Evolution and new frontiers of histology in bio-medical research.

Authors:  Maria Mazzarini; Mario Falchi; Daniele Bani; Anna Rita Migliaccio
Journal:  Microsc Res Tech       Date:  2020-09-11       Impact factor: 2.769

8.  A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis.

Authors:  Maria Zingariello; Alessandra Ruggeri; Fabrizio Martelli; Manuela Marra; Laura Sancillo; Ilaria Ceglia; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2015-12-25

Review 9.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

Review 10.  Megakaryocyte emperipolesis: a new frontier in cell-in-cell interaction.

Authors:  Pierre Cunin; Peter A Nigrovic
Journal:  Platelets       Date:  2019-11-21       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.